[Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1679-83. doi: 10.7534/j.issn.1009-2137.2015.06.028.
[Article in Chinese]

Abstract

Objective: To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years.

Methods: Four elderly patients with AML were treated in Chinese Second Artillery General Hospital from August 2008 to September 2013. The proportion of male to female was 1 : 3 and the median age 83 (80-85) years. All patients received programmed infusions of G-PBHSC after MA regimen chemotherapy without graft-versus-host disease (GVHD) prophylaxis. After complete remission (CR), patients only received G-PBHSC infusion without chemotherapy.

Results: Three cases achieved CR and their disease free survival (DFS) time was 18, 8, 6 months, respectively. 1 case did not reach remission after 2 cycles chemotherapy. The median overall survival (OS) time was 10 (3-20) months. No GVHD was observed in any of the patients during treatment. Concludsion: The combination of chemotherapy and programmed haploidentical G-PBHSC infusion is an alternative approach for AML patients aged over 80 years.

MeSH terms

  • Aged, 80 and over
  • Combined Modality Therapy
  • Cytarabine
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease
  • Granulocyte Colony-Stimulating Factor
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells
  • Humans
  • Leukemia, Myeloid, Acute*
  • Male
  • Mitoxantrone
  • Remission Induction

Substances

  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Mitoxantrone